We were pleased to participate in today’s ShareCafe Sip & Learn webinar, where Saurabh Jain, Executive Chairman of Opyl (ASX: OPL), presented alongside Thian Chew, CEO of Invion Limited (ASX: IVX). The event brought together an audience of investors and financial advisors to explore advancements in clinical trials and oncology innovation. Saurabh shared how TrialKey, our AI-driven clinical trial design platform, addresses key challenges in trial optimisation. By analysing extensive datasets, TrialKey aims to support better trial designs and reduce inefficiencies across the clinical development process. Thian highlighted Invion’s progress with their photodynamic therapy platform and ongoing clinical programs targeting non-melanoma skin cancers and other indications. The presentations highlighted the critical role of innovation and collaboration in advancing clinical research and improving outcomes for patients. Thank you to ShareCafe for facilitating this opportunity! Opyl investor enquiries: bernice@trialkey.ai Book a TrialKey demo: https://appt.link/minhthu #clinicaltrials #biotech #aiinhealthcare #asx #medicalresearch #trialdesign #innovation #biopharma #pharma #smallcap #biotechinvestment
TrialKey
Technology, Information and Internet
St Kilda, Victoria 862 followers
AI-powered clinical trials developed by Opyl.
About us
TrialKey, the global leader in AI-driven biostatistical validation, transforms clinical trial designs by leveraging its advanced simulator to analyse real-world data. Designed for Clinical Research Organisations (CROs), pharmaceutical companies, and trial sponsors, TrialKey enhances success probabilities across all phases of clinical research, offering a comprehensive suite of global trial design solutions. Key features include the TrialGen module, which provides data-backed recommendations on study type, enrolment numbers, inclusion/exclusion criteria, endpoints, and optimal trial durations. TrialKey’s simulation capabilities also refine intervention models, masking types, and resource allocation, reducing costly amendments and accelerating market entry for a competitive edge in clinical research. With market-leading accuracy, TrialKey achieves over 92% in forecasting trial completion. Each trial is simulated 10,000 times, delivering robust, data-driven biostatistical validation to optimise designs. By analysing extensive datasets from over 350,000 clinical trials and 1300+ variables, TrialKey offers critical insights for strategic planning and decision-making. This includes competitor benchmarking, success probability distributions, and mapping competitor activities. Globally applicable and scalable, TrialKey caters to companies of all sizes, whether managing a handful of trials or thousands. Its user-friendly design and comprehensive support empower clinicians, researchers, and investors to make informed decisions, streamline trial outcomes, and drive medical research forward. Book a demo: https://appt.link/meet-with-trial-key-team Sales enquiries: minhthu.caoxuan@opyl.ai Marketing enquiries: bernice.averion@opyl.ai
- Website
-
https://www.trialkey.ai
External link for TrialKey
- Industry
- Technology, Information and Internet
- Company size
- 11-50 employees
- Headquarters
- St Kilda, Victoria
- Type
- Privately Held
- Founded
- 2023
- Specialties
- clinical trial design, prediction, clinical research, medical research, and competitor analysis
Locations
-
Primary
Get directions
105 Wellington St
St Kilda, Victoria 3182, AU
Employees at TrialKey
-
Saurabh Jain
Executive Chairman (ASX: OPL) | Board Member
-
Bernice Averion
Head of Marketing & Communications (ASX: OPL) Clinical Trial SaaS - Trial Design Biostatistical Validation and Trial Performance Simulations
-
Mae-vel Catcho
BSBA Financial Management Graduate at Silliman University | Marketing Manager | Project Manager
Updates
-
Through our partnership with Commercial Eyes Pty Ltd, Opyl’s TrialKey enhances in-licensing assessments with cutting-edge AI insights. Together, we deliver a powerful combination of advanced analytics, qualitative research, and industry expertise to help clients navigate complex decisions with clarity and confidence. With TrialKey, identifying high-potential assets and evaluating market viability has never been smarter or more efficient. Marketing and investor enquiries: bernice@trialkey.ai Book a demo: https://appt.link/minhthu #clinicaltrials #pharmaceuticals #biotech #aiinnovation #healthcarestrategy #partnershippower #datadriven #licensingdecisions
-
With data on 2.69 billion patients, TrialKey offers unparalleled insights into patient populations. Tailor inclusion and exclusion criteria, optimize recruitment, and ensure your trial design aligns with real-world patient demographics and health trends. Book a meeting via: https://appt.link/minhthu #clinicaltrials #biotech #patientdata #precisionmedicine #healthanalytics #healthcareai
-
-
Join Saurabh Jain, Executive Chairman of Opyl, as he presents at the ShareCafe Webinar, showcasing TrialKey, a cutting-edge AI solution revolutionising clinical trial design and success prediction. When: 12:30 PM AEDT, Friday, 29 November 2024 Register here to attend: https://lnkd.in/g4jEAca8 #opyl #trialkey #sharecafe #clinicaltrials #biotechinvestment #aiinvestment #asx #investmentopportunity #biotech #pharmaceuticals #biotech #clinicalresearch
-
-
Poor planning and design flaws lead to costly amendments, averaging hundreds of thousands of dollars each. TrialKey addresses these challenges with TrialGen, which automates protocol design using AI. This includes defining precise patient inclusion/exclusion criteria and selecting the best endpoints. By leveraging real-world data, TrialGen ensures optimal resource allocation and significantly reduces the need for amendments, enhancing trial efficiency and success rates. 🔗 Book a demo: https://appt.link/minhthu #clinicaltrials #trialgen #aiforhealth #clinicalsuccess #healthtech #datadriven
-
-
We’re pleased to announce a new Service Level Agreement with Southern Clinical Development Consulting, alongside Dr Khalid Abubaker. Through our TrialKey platform, Southern CDC will gain robust AI-driven support enhancing their clinical trial support and optimisation capabilities. Each TrialKey report delivers actionable insights backed by real-world data and predictive modelling, enhancing trial efficiency and precision. OPL investor and marketing enquiries: bernice@trialkey.ai Book a demo: https://appt.link/minhthu #clinicaltrials #datadriven #biotech #clinicalresearch #healthtech #aiinhealthcare #trialdesign #regulatoryscience #precisionmedicine #collaborativeinnovation
-
-
TrialKey identifies over 200 market inflection points annually, highlighting high-potential US and AU biotech and pharmaceutical stocks. By predicting clinical trial outcomes and success probabilities, our platform enables investors to make informed and timely investment decisions. Whether a trial succeeds or fails has a big impact on the movement of a small to medium biotech's stock price. Stay ahead in the biotech market with TrialKey's predictive insights. Discover how: https://lnkd.in/gQXfrCV5 #biotechstocks #investment #clinicaltrials #ai #healthtech #medicalresearch #biotech #innovation #marketinsights #trialkey
-
-
Selecting the right trial duration is critical for the success of any clinical study. TrialKey's TrialGen simulator is designed to help you make informed decisions by normalising trial success rates to a one-year duration. This approach allows us to identify the optimal timeframe tailored to your specific study. Our advanced AI-driven analysis takes into account various factors, including the therapeutic area, study objectives, and a wealth of historical data, to recommend the most effective trial duration. We aim to ensure that your trial is neither too short to produce meaningful results nor too long to drain valuable resources. 🔗 Book a demo: https://appt.link/minhthu #trialduration #healthtech #datadrivendecisions #clinicalresearch #trialgen #biostatistics
-
-
TrialKey harnesses 608,400,000 unique data points to power AI-driven insights for your clinical trials. Make confident design decisions based on comprehensive analytics that cover all trial variables, optimizing every element for success. Let’s discuss how we can enhance your clinical trial designs and research. Book a meeting via: https://appt.link/minhthu #clinicaldesign #biopharma #healthdata #aiinsights #clinicalsuccess #datadrivendesign
-
-
Wonderful lunch time catch up between Minh-Thu C. from TrialKey and our clients Dr. Stephane Verhaeghe MD and Dan Stevens from Brain Vector! We always enjoy reconnecting with our clients and partners, hearing about the latest progress on projects we’ve worked on together, and exploring fresh ways we can support their new ideas and goals with tailored solutions. Opyl investor and marketing enquiries: bernice@trialkey.ai Book a demo: https://appt.link/minhthu #clinicaltrials #trialkey #biotech #medtech #medicaldevice #healthtech #depression #anxiety #neurodevice #brainvector #medicalresearch
-